Suven Life Sciences to Present Key Alzheimer's Clinical Data at CTAD-2026
Suven Life Sciences Ltd 路 Press Release 路 16 Nov 2026, 4:28 pm
Suven Life Sciences to Present Key Alzheimer's Clinical Data at CTAD-2026 Suven Life Sciences announced on 16th Nov'26 that it will present clinical trial progress for two key CNS drug candidates at the CTAD conference in Boston. The company completed enrollment for its global Phase-3 study of Masupirdine (SUVN-502) targeting agitation in Alzheimer's dementia, with topline results scheduled for Q2'27 and no major safety concerns identified to date. Additionally, Phase-1 SAD and MAD safety, tolerability, and pharmacokinetic data for Tenaclidine (SUVN-I6107) will be presented as it prepares to advance into patient trials.
Original exchange filing (PDF)
More announcements from Suven Life Sciences Ltd
- Please find enclosed the Revised News Release of our company 路 16 Nov 2026
- Please find enclosed News Release of our Company 路 12 Nov 2026
- Monitoring Agency Report for the quarter ended 30th September, 2026 路 06 Nov 2026
- Un-audited financial results for the quarter and half year ended 30th September 2026 路 05 Nov 2026
- Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026 路 05 Nov 2026
- Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
- SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
